Metabolon

141 articles with Metabolon

• Metabolon's Metabolomic Platform and Services Cited in More Than 3,000 Peer-Reviewed Articles across Life Sciences, Pharmaceutical/Biotech, and Applied Sciences

  3/29/2023

  Metabolon, Inc., the global leader in providing metabolomics solutions that advance a wide variety of research, diagnostic, therapeutic development, and precision medicine applications, announced their metabolomics platform outputs and related services have been cited in more than 3,000 peer-reviewed journals.

• Metabolon Secures $25 Million of Funding to Accelerate Growth

  1/24/2023

  Metabolon, Inc., the global leader in providing metabolomics solutions that advance a wide variety of research, diagnostic, therapeutic development, and precision medicine applications, announced that it has closed on $25 million of additional equity funding.

• Metabolon Expands Data Access Strategy to Include Health for Life in Singapore (HELIOS) Study

  9/27/2022

  Metabolon, Inc. announced a new partnership with the Lee Kong Chian School of Medicine at Nanyang Technological University, Singapore to identify biomarkers using data from the Health for Life in Singapore study.

• Metabolon Partners with the University of Oxford Parkinson's Disease Centre

  8/23/2022

  Metabolon, Inc. announced it is partnering with the University of Oxford Parkinson's Disease Centre to identify metabolomic biomarkers related to Parkinson's disease progression and prediction and to detect new therapeutic targets.

• Metabolon Announces Joint Development Agreement with Mayo Clinic to Create New Diagnostic Tests

  8/9/2022

  Metabolon , Inc. today announced a joint development agreement with Mayo Clinic to develop novel metabolomic biomarker diagnostic tests.

• Metabolon Appoints Tom Houseman as Vice President of Operations

  7/25/2022

  Metabolon , Inc., the global leader in providing metabolomics solutions that advance drug development and precision medicine, today announced that Tom Houseman has been appointed Vice President of Operations.

• Metabolon Partnership with University of Maryland School of Medicine Amish Research Program Leverages Metabolomics to Identify Novel Biomarkers

  6/21/2022

  Metabolon, Inc., the global leader in metabolomics solutions advancing drug development and precision medicine, is partnering with the University of Maryland School of Medicine to bring the latest technological advances to the School's Amish Research Program.

• Metabolon Appoints New Vice President of Global Marketing, Supporting Commercial Product Expansion

  5/19/2022

  Metabolon, Inc., the global leader in providing metabolomics solutions that advance drug development and precision medicine, has appointed Sean Iverson as Vice President of Global Marketing.

• Metabolon Announces Chief Financial Officer TransitionGerald M. Haines II appointed CFO effective April 1, 2022

  2/14/2022

  Metabolon , Inc. announces the appointment of Gerald M. Haines II as Chief Financial Officer (CFO), as current CFO John Kurtzweil prepares to retire.

• Metabolon to Power Metabolomic Enriched Population Health Studies at FinnGen

  1/25/2022

  Metabolon Inc., through its wholly-owned subsidiary, Metabolon GmbH, announces a multi-year collaboration with the FinnGen study in Finland to provide metabolomics data for population health studies to improve understanding of human health.

• Metabolon Continues Investments in Scientific Innovation with Appointment of Rangaprasad (Ranga) Sarangarajan, Ph.D., in New Leadership Role as Chief Scientific Officer

  10/14/2021

  Metabolon, Inc. has appointed Rangaprasad (Ranga) Sarangarajan , Ph.D., to the newly created role of Chief Scientific Officer (CSO).

• Metabolon Collaborates with Cleveland Clinic to Enable Novel Discoveries

  2/18/2021

  Metabolon, Inc. has entered into to a multi-year collaborative agreement with Cleveland Clinic to provide Metabolon's Precision Metabolomics™ services in support of drug development and related research efforts.

• National Institute of Allergy and Infectious Disease (NIAID) Selects Metabolon, Inc. for COVID-19 Study

  11/23/2020

  Metabolon , Inc. will participate in the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, Immunophenotyping Assessment in a COVID-19 Cohort, or IMPACC , study (grant no: 5U19AI118602-04). Analysis of the data generated from this novel coronavirus (SARS-CoV-2) study,

• Metabolon, Inc. and DNA Genotek Collaborate on First Ambient-Temperature Microbiome Sampling Solution for Metabolomics

  6/17/2020

  OMNImet™·GUT expands access to critical metabolomic analysis with development of in-home fecal collection device

• Major Players Operating in the Global Metabolomics Market 2019-2023 | Technavio

  7/25/2019

  Many investigators and researchers are using metabolomics in the study of chronic diseases such as cancer, which helps them to discover new biomarkers for cancer.

• Partnership created to uncover reasons for frailty in aging populations

  7/10/2019

  Three national research groups and a leading health technology company are teaming together to discover the frailty biomarkers that may shed light on why some people become frail, determine the severity of frailty and what can be done to help avoid the condition.

• Renowned Pharmaceutical R&D Expert Jan Lundberg Joins Metabolon’s Board of Directors

  2/20/2019

  Metabolon, the world leader in metabolomics, today announced that Dr. Jan Lundberg, Ph.D. has joined its Board of Directors.

• 

  BioSpace Movers and Shakers: Jan. 25

  1/25/2019

  Movers and Shakers is BioSpace's weekly roundup of leadership appointments and changes within the biopharma world. Included this week are Genentech, Editas, Sage, Sangamo, and more.

• Metabolon Appoints Michael Rasche as President of International Business

  1/21/2019

  He will lead all of Metabolon's international business activities with a strong focus on customer and team expansion.

• Metabolon to Provide Metabolomic Profiling for the VA's Million Veteran Program

  4/20/2018

   Metabolon, Inc. announced that the U.S. Department of Veterans Affairs (VA) has been contracted through its alliance with AKESOgen, a leader in genomics, to perform large-scale metabolomic profiling on biological samples from U.S. veterans as part of the Million Veteran Program (MVP).